2975

Myosin Light Chain 2v (D5I1C) (Cardiac Isoform) Rabbit mAb



Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: M R	Sensitivity: Endogenous	MW (kDa): 20	Source/Isotype: Rabbit IgG	UniProt ID: #P51667	Entrez-Gene Id: 17906		
Product Usage Information		Application Western Blotting			Dilution 1:1000			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Sensitivity		Myosin Light Chain 2v (D5I1C) (Cardiac Isoform) Rabbit mAb recognizes endogenous levels of total myosin light chain 2v (cardiac isoform) protein.						
Source / Purific	cation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of mouse myosin light chain 2v (cardiac isoform) protein.						
Background		Myosin is composed of six polypeptide chains: two identical heavy chains and two pairs of light chains. Myosin light chain 2 (MLC2), also known as myosin regulatory light chain (MRLC), RLC, or LC20, has many isoforms with varying tissue distribution. Smooth muscle MLC2 is phosphorylated at Thr18 and Ser19 by myosin light chain kinase (MLCK) in a Ca ²⁺ /calmodulin-dependent manner (1). These phosphorylation events are correlated with myosin ATPase activity and smooth muscle contraction (2). Striated muscle contraction is regulated by the troponin-tropomyosin complex in thin actin filaments and by binding of Ca ²⁺ to troponin C (3). Two types of myosin light chain are expressed in the heart, with myosin light chain 2v (MYL2, MLC-2v) expression restricted to the ventricles and myosin light chain 2a (MYL7, MLC-2a) found specific to the atria. Mutations in the corresponding <i>MYL2</i> gene are found in patients diagnosed with a form of hypertrophic cardiomyopathy characterized by thickening of the mid-left ventricle.						
Background Re	eferences	1. Ikebe, M. and Harts 2. Tan, J.L. et al. (1992) 3. Tsukamoto, O. and	Annu Rev Biochen		l.			
Species Reactiv	vity	Species reactivity is de	etermined by testin	g in at least one approve	ed application (e.g.,	western blot).		
Western Blot B	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ey	W: Western Blotting						
Cross-Reactivit	ty Key	M: Mouse R: Rat						
Trademarks ar	nd Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		All other trademarks a more information.	are the property of	their respective owners.	Visit cellsignal.com	/trademarks for		
Limited Uses		the following terms ap terms and conditions separately accepted ir force or effect.	oply to Products pro that are in addition writing by a legall	a writing signed by a leg ovided by CST, its affiliate to, or different from, th y authorized representa	es or its distributors ose contained here tive of CST, are rejec	s. Any Customer's in, unless cted and are of no		
		approved, cleared, or purpose. Customer sh	licensed by the FDA nall not use any Pro	lse Only or a similar labe A or other regulatory for duct for any diagnostic o g statement. Products so	eign or domestic er or therapeutic purp	itity, for any ose, or otherwise in		

Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.